Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



As described below under Item 5.07 of this Current Report on Form 8-K, on
February 28, 2023, European Biotech Acquisition Corp. (the "Company" or "EBAC")
convened an extraordinary general meeting (the "Extraordinary General Meeting")
to approve, among other things, the previously announced business combination of
the Company and Oculis SA (the "Business Combination").

Upon the conclusion of the Extraordinary General Meeting, each of
(i) Mr. Martijn Kleijwegt, (ii) Mr. Mark Wegter, (iii) Mr. Volkert Doeksen and
(iv) Mr. Onno van de Stolpe resigned as members of the board of directors of the
Company (the "Board"), effective upon the conclusion of the Extraordinary
General Meeting. All such resignations were voluntary and not the result of any
disagreement with the operations, policies or practices of the Company.

Also upon the conclusion of the Extraordinary General Meeting, the Company
appointed Mr. Riad Sherif and Mr. Anthony Rosenberg to serve as members of the
Board, effective upon the conclusion of the Extraordinary General Meeting. In
connection therewith, the Company appointed each of Mr. Sherif and Mr. Rosenberg
to serve as members of the audit committee of the Board.

Item 5.07. Submission of Matters to a Vote of Security Holders.

Set forth below are the final voting results for each of the proposals submitted to a vote of the shareholders of the Company at the Extraordinary General Meeting:



                                                    Votes For        Votes Against       Abstentions
1.   Business Combination Proposal - A proposal
     to, as an ordinary resolution, authorize,
     approve and confirm in all respects that
     the Business Combination Agreement, dated
     as of October 17, 2022 (as it may be            10,076,817             936,889                 0
     amended, supplemented, or otherwise
     modified from time to time), by and between
     European Biotech Acquisition Corp. and
     Oculis SA, and the transactions
     contemplated thereby.



                                                    Votes For        Votes Against       Abstentions
2.   Merger Proposal - A proposal to, as a
     special resolution, authorize, approve and
     confirm in all respects that European
     Biotech Acquisition Corp. be and is hereby
     authorized to enter into the Plan of
     Merger, and that the merger of Merger Sub 1     10,076,817             936,889                 0
     with and into EBAC, the separate entity
     existence of Merger Sub 1 will cease, and
     EBAC will be the surviving company and a
     direct wholly owned subsidiary of Oculis
     Holding AG.



                                                    Votes For        Votes Against       Abstentions
3.   Adjournment Proposal - A proposal to, as an
     ordinary resolution, adjourn the
     Extraordinary General Meeting to a later
     date or dates to the extent reasonable
     (i) to ensure that any supplement or
     amendment to the proxy statement/prospectus
     is provided to EBAC shareholders, (ii) in
     order to solicit additional proxies from
     EBAC shareholders in favor of the Business      10,076,817             936,889                 0
     Combination Proposal and the Merger
     Proposal or for any other reason in
     connection with the transactions
     contemplated by the Business Combination
     Agreement or (iii) if EBAC shareholders
     redeem an amount of EBAC Class A Common
     Stock such that the Minimum EBAC Cash
     Condition would not be satisfied.


Based upon the submission of proxies and ballots, a majority of the shares of
EBAC ordinary shares issued and outstanding and entitled to vote at the close of
business on the record date were present at the Extraordinary General Meeting by
proxy or by attendance via the virtual meeting website, which constituted a
quorum. Proposal 1 was approved by the required vote. Proposal 2 was approved by
the required vote. Proposal 3 was approved by the required vote.

--------------------------------------------------------------------------------

Item 8.01. Other Events.



In connection with the shareholder vote at the Extraordinary General Meeting,
EBAC's public shareholders had the right to elect to redeem all or a portion of
their Class A ordinary shares for a per share price calculated in accordance
with EBAC's organizational documents. EBAC's public shareholders holding
11,505,684 Class A ordinary shares validly elected to redeem their public
shares.

The Closing is expected to occur on or about March 2, 2023, subject to the satisfaction or waiver of the conditions with respect to the Business Combination.

Item 9.01. Financial Statements and Exhibits

Exhibit

No. Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses